It’s time for Stuart Peltz to take the Congressional hot seat on drug pricing.
The CEO of PTC Therapeutics acquired Marathon’s steroid deflazacort for $140 million up front a few days ago with an eye to sell it to a small population of Duchenne muscular dystrophy patients. And that comes with as much of a glaring spotlight as Senator Bernie Sanders and Rep. Elijah Cummings can bring to it.
